Zhang Le, Zhao Haifeng, Li Xiaowu, Xia Bing, Zheng Hong, Li Haixin, Sun Baocun, Zhang Yizhuo
Department of Hematological Oncology, Tianjin Cancer Institute and Hospital, Tianjin 300060, China.
Email:
Zhonghua Zhong Liu Za Zhi. 2014 Oct;36(10):755-60.
To explore the expression of Bcl-2 mRNA and its effect on prognosis of patients with primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL).
Real time quantitative PCR was used to determine the expression of Bcl-2 mRNA in 40 PGI-DLBCL patients and 17 healthy controls. The association of Bcl-2 expression with clinicopathological features and prognosis of the patients was analyzed.
The expression level of Bcl-2 mRNA in PGI-DLBCL patients was 1.03 ± 0.93, significantly higher than that of the controls (0.41 ± 0.21) (P < 0.05). The expression of Bcl-2 mRNA in stage IIE-IV patients (1.28 ± 1.01) was significantly higher than that in the stage I-II2 patients (0.62 ± 0.61) (P < 0.05). The expression of Bcl-2 mRNA in patients with international prognostic index (IPI) score >2 (1.95 ± 1.27) was significantly higher than those with IPI score ≤ 2 (0.86 ± 0.75)(P < 0.05). The expression of Bcl-2 mRNA in patients with complete remission (CR) (0.71 ± 0.58) was significantly lower vs. 2.42 ± 0.91 in patients with no CR (P < 0.05). Univariate analysis indicated that β2-MG, IPI score>2, the Lugano staging, and Bcl-2 mRNA expression were associated with overall survival (OS) and progression-free survival (PFS) (P < 0.05). Multivariate analysis indicated that IPI score>2 was independently associated with OS (P < 0.05), and both IPI score >2 and Bcl-2 mRNA expression were independently associated with PFS (P < 0.05).
The expression of Bcl-2 mRNA in the tumor tissue of PGI-DLBCL patients is significantly higher than that in controls. PGI-DLBCL patients with higher expression of Bcl-2 have a poor chemotherapy response and inferior prognosis. IPI score >2 and higher expression of Bcl-2 mRNA are independent poor prognostic factors for PFS in PGI-DLBCL patients.
探讨Bcl-2 mRNA的表达及其对原发性胃肠道弥漫性大B细胞淋巴瘤（PGI-DLBCL）患者预后的影响。
采用实时定量PCR检测40例PGI-DLBCL患者及17例健康对照者Bcl-2 mRNA的表达。分析Bcl-2表达与患者临床病理特征及预后的相关性。
PGI-DLBCL患者Bcl-2 mRNA表达水平为1.03±0.93，显著高于对照组（0.41±0.21）（P<0.05）。ⅡE-IV期患者Bcl-2 mRNA表达（1.28±1.01）显著高于Ⅰ-II2期患者（0.62±0.61）（P<0.05）。国际预后指数（IPI）评分>2的患者Bcl-2 mRNA表达（1.95±1.27）显著高于IPI评分≤2的患者（0.86±0.75）（P<0.05）。完全缓解（CR）患者Bcl-2 mRNA表达（0.71±0.58）显著低于未达到CR的患者（2.42±0.91）（P<0.05）。单因素分析表明，β2-MG、IPI评分>2、卢加诺分期及Bcl-2 mRNA表达与总生存期（OS）和无进展生存期（PFS）相关（P<0.05）。多因素分析表明，IPI评分>2与OS独立相关（P<０.０５），IPI评分>2和Bcl-2 mRNA表达均与PFS独立相关（P<0.05）。
PGI-DLBCL患者肿瘤组织中Bcl-2 mRNA表达显著高于对照组。Bcl-2表达较高的PGI-DLBCL患者化疗反应差，预后不良。IPI评分>2及Bcl-2 mRNA高表达是PGI-DLBCL患者PFS的独立不良预后因素。
